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ABSTRACT  
  Bacteriophages, or “phages,” are a category of highly adept and 
adaptable viruses that can infect and kill bacteria. With concerns over 
the burgeoning antibiotic-resistance crisis looming in recent years, 
scientists and policymakers have expressed a growing interest in 
developing novel treatments for bacterial infections that utilize 
bacteriophages. Because of the great expense associated with bringing 
a new drug to market, patents are usually considered the gold standard 
for incentivizing research and development in the pharmaceutical field. 
Absent such strong protection for a developer’s front end investment, 
pharmaceutical development remains financially risky and 
unattractive. Unfortunately, recent Supreme Court jurisprudence 
analyzing patentable subject matter under 35 U.S.C. § 101 has cast 
doubt on whether phage therapeutics would be eligible for strong 
patent protection. In order for the promise of phage therapeutics to 
become a reality, alternative protections or incentives are likely 
necessary. Such a framework would likely include trade secrecy, 
regulatory exclusivities, research support, alternative payment models, 
or some combination thereof. 
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INTRODUCTION 
In 2017, headlines across the country praised a miraculous sewer 
sludge that brought a man back from the brink of death when all else 
failed.1 Many months before, sixty-nine-year-old Tom Patterson had 
developed a bacterial infection caused by an often deadly, multidrug-
resistant strain of Acinetobacter baumannii.2 He was admitted to the 
hospital with intense abdominal pain and a fever, where he began 
projectile vomiting black bile “like something out of ‘The Exorcist.’”3 
After a last resort combination of potent, high-risk antibiotics failed, 
Mr. Patterson’s condition worsened, and he slipped into a coma.4 
Although told to prepare for the worst, Mr. Patterson’s wife, infectious 
disease epidemiologist Dr. Steffanie Strathdee, refused to give up; she 
began researching alternative treatments.5 Dr. Strathdee found 
promising reports of a type of virus known as a bacteriophage 
(“phage”) that can infect and kill bacteria, thereby curing antibiotic-
resistant infections.6 She began contacting countless researchers and 
labs with the hope of finding a phage that could target A. baumannii.7 
Researchers at Texas A&M University and the U.S. Naval Research 
Laboratory in Maryland responded, identifying a few promising phage 
candidates that had been isolated from samples taken from a local 
sewage plant, as well as some that were stored in existing phage 
libraries and labs.8 Dr. Strathdee secured emergency FDA approval to 
use the phages, and Mr. Patterson was injected with two individualized 
 
 1. Azeen Ghorayshi, Her Husband Was Dying From a Superbug. She Turned  
to Sewer Viruses Collected by the Navy, BUZZFEED (May 6, 2017), 
https://www.buzzfeed.com/azeenghorayshi/navy-phage-viruses-for-antibiotics-crisis?utm_term 
=.dh0aywqDM#.vq8BbMY4a [https://perma.cc/F5X2-PZLS] (detailing how a bacteriophage 
found in sewage helped cure a man’s life-threatening bacterial infection); Lauren Weber, Sewage 
Saved This Man’s Life. Someday It Could Save Yours, HUFFINGTON POST (May 11, 2017), 
https://www.huffingtonpost.com/entry/antibiotic-resistant-superbugs-phage-therapy_us_ 
5913414de4b05e1ca203f7d4 [https://perma.cc/N8NV-DDTB] (same). 
 2. Scott LaFee & Heather Buschman, Novel Phage Therapy Saves Patient with Multidrug-
Resistant Bacterial Infection, UC SAN DIEGO HEALTH NEWSROOM (Apr. 25, 2017), 
https://health.ucsd.edu/news/releases/Pages/2017-04-25-novel-phage-therapy-saves-patient-with-
multidrug-resistant-bacterial-infection.aspx [https://perma.cc/AH2E-7EEP]. 
 3. Weber, supra note 1. 
 4. LaFee & Buschman, supra note 2. 
 5. Weber, supra note 1. 
 6. Id. 
 7. Id. 
 8. Id.  
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phage cocktails.9 After being in a coma for two months, he woke up 
three days after the phages were administered.10 
Mr. Patterson’s experience illustrates the urgency of the bacterial-
resistance crisis. With antibiotic resistance becoming an increasingly 
lethal and prevalent threat to global public health,11 innovative 
antimicrobial products that are capable of treating these dangerous 
infections are more important now than ever before. Phages have 
demonstrated their efficacy as highly targeted, potent, and adaptable 
killers of antibiotic-resistant bacteria. These viruses depend on their 
ability to infect bacteria in order to proliferate, and as such have 
evolved diverse mechanisms for breaking through bacterial defenses.12 
However, they remain relatively harmless to humans, leading 
researchers in recent years to identify phage therapeutics as a possible 
panacea for the antibiotic-resistance crisis.13 However, this solution 
depends on the development of viable phage products, an area that has 
seen little investment by biotechnology and pharmaceutical 
companies, regardless of its medical promise.14 This lack of innovation 
is likely due in large part to the dubious patentability of phages and 
phage therapies following the Supreme Court’s decision in Association 
for Molecular Pathology v. Myriad Genetics, Inc.,15 which held that 
naturally occurring products are not patent-eligible subject matter.16 
This Note is the first to closely analyze the patentability of phage 
therapies, to discuss the impact of uncertain patentability on 
innovation in the phage therapeutics field, and to suggest possible 
nonpatent alternatives.  
 
 9. LaFee & Buschman, supra note 2. 
 10. Id. 
 11. See C. Lee Ventola, The Antibiotic Resistance Crisis, Part 1: Causes and Threats, 40 
PHARMACY & THERAPEUTICS 277, 283 (2015) (“Rapidly emerging resistant bacteria threaten the 
extraordinary health benefits that have been achieved with antibiotics.” (citation omitted)). 
 12. Derek M. Lin, Britt Koskella & Henry C. Lin, Phage Therapy: An Alternative to 
Antibiotics in the Age of Multi-Drug Resistance, 8 WORLD J. GASTROINTESTINAL 
PHARMACOLOGY & THERAPEUTICS 162, 164 (2017), https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC5547374 [https://perma.cc/AAZ4-KAWB] (“Bacteria have evolved numerous 
mechanisms to resist infection by lytic phages, and phages have an equally impressive diversity of 
mechanisms for breaking this resistance.”). 
 13. Sara Reardon, Modified Viruses Deliver Death to Antibiotic-Resistant Bacteria, NATURE: 
NEWS (June 21, 2017), https://www.nature.com/news/modified-viruses-deliver-death-to-
antibiotic-resistant-bacteria-1.22173 [https://perma.cc/4NCQ-5JEA]. 
 14. See id. (explaining that the “development of phage therapy has been slow”). 
 15. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013). 
 16. Id. at 580.  
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This Note argues that to bring about the promise of phage 
therapies for the treatment of antibiotic-resistant infections, the 
traditional patent-centric model for stimulating drug innovation is 
insufficient. Alternative protections or incentives, such as trade 
secrecy, regulatory exclusivities, research support, alternative payment 
models, or some combination thereof, are likely necessary to spur 
phage therapy innovation. Part I explains the development of 
antibiotic resistance in bacteria and the growing threat it poses to 
global health. Part II discusses the unique characteristics of phages and 
the benefits and challenges of creating phage-based treatments. Part 
III analyzes the murkiness of recent patent-eligibility jurisprudence 
and the weak protection it offers for phage therapies. Finally, Part IV 
goes on to address the availability of and need for alternative 
protections and incentives that stimulate phage therapy innovation, 
including trade secrecy, regulatory exclusivities, governmental 
research support and funding, and alternative payment models. 
I.  THE GLOBAL ANTIBIOTIC RESISTANCE CRISIS 
Like war, religion, and technology, humanity has been 
inextricably intertwined with, and shaped by, bacterial disease. Though 
modern antibiotics have provided the human race with great relief 
from bacterial onslaught, these simple microorganisms have recently 
begun developing ways to slip through the chinks in our antibiotic 
armor.  
A. Bacterial Diseases and the Discovery of Penicillin  
Many highly dangerous infectious diseases are caused by 
bacteria—a group of microscopic, unicellular prokaryotes that are 
defined by their lack of a membrane-bound nucleus and other 
specialized organelles that are found in plant and animal cells.17 
Bacteria’s small size and flexible metabolic capabilities promote fast 
replication and adaptability, allowing these organisms to rapidly 
establish a presence in a wide variety of environmental conditions.18 
 
 17. Kara Rogers & Robert J. Kadner, Bacteria, ENCYCLOPEDIA BRITANNICA, 
https://www.britannica.com/science/bacteria [https://perma.cc/XV2K-4TK8]. 
 18. See, e.g., Robin Andrews, Living in Hell: The Possibility of Life Inside a Volcano, FORBES 
(Apr. 15, 2017), https://www.forbes.com/sites/robinandrews/2017/04/15/living-in-hell-the-
possibility-of-life-inside-a-volcano/#56725cc51c1d [https://perma.cc/VD7E-EQF4] (noting that 
bacterial life is capable of surviving even in “Yellowstone’s superheated, anoxic, acidic hot 
springs”); Olivia U. Mason et al., First Investigation of the Microbiology of the Deepest Layer of 
Ocean Crust, PLOS ONE, Nov. 2010, http://journals.plos.org/plosone/article?id=10.1371/ 
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Their adaptability and symbiotic coevolution with life and the 
environment has aided the proliferation of the estimated five million 
trillion trillion bacteria existing today.19 According to Andrew H. 
Knoll, professor of biology at Harvard University, “[w]e definitely live 
in a bacterial world.”20 
While most bacterial strains have either a neutral or beneficial 
impact on humans, less than one percent are pathogenic.21 Bacterial 
infections cause an array of symptoms and can result in death.22 Many 
profound episodes of human loss throughout history can be attributed 
to bacterial infections. One of the most infamous catastrophes, the 
Black Death of 1347–1351, was caused by the bacterium Yersinia pestis 
and resulted in the death of an estimated 30–50 percent of the 
European population, and up to 100 million people worldwide.23 
During humanity’s earlier days, similar epidemics of leprosy, plague, 
syphilis, cholera, and typhoid fever were the norm,24 profoundly 
impacting the development of the world’s habits, commerce, and 
culture.25  
A monumental turning point came in 1928, when an accidentally 
contaminated petri dish led to the discovery of penicillin.26 By 1942, 
penicillin was deployed to save the life of a young woman dying of 
 
journal.pone.0015399 [https://perma.cc/UV3B-KM7D] (describing the bacterial communities 
found in the deepest layer of the oceanic crust); Arie Nissenbaum, The Microbiology and 
Biogeochemistry of the Dead Sea, 2 MICROBIAL ECOLOGY 139 (1975) (discussing bacterial 
cultures found in the hypersaline Dead Sea). 
 19. Planet Bacteria, BBC NEWS (Aug. 25, 1998), http://news.bbc.co.uk/2/hi/
science/nature/158203.stm [https://perma.cc/H5LY-BZ4V]. 
 20. NOVA, How Did Life Begin?, PBS (July 1, 2004), http://www.pbs.org/wgbh/
nova/evolution/how-did-life-begin.html [https://perma.cc/R8EM-CVUZ]. 
 21. Bacterial Infections, PUBMED HEALTH, https://www.ncbi.nlm.nih.gov/
pubmedhealth/PMHT0024516 [https://perma.cc/J4WJ-VQK8]. 
 22. Id. 
 23. Kirsten I. Bos et al., A Draft Genome of Yersinia Pestis from Victims of the Black Death, 
478 NATURE 506, 506 (2011); TEXTBOOK EQUITY, 2 COLLEGE BIOLOGY 602–03 (2014) (ebook). 
 24. Philip S. Brachman, Editorial, Infectious Diseases – Past, Present, and Future, 32 INT’L J. 
EPIDEMIOLOGY 684, 684 (2003). 
 25. See Maxine Whittaker, How Infectious Diseases Have Shaped Our Culture, Habits and 
Language, THE CONVERSATION (July 12, 2017), https://theconversation.com/how-infectious-
diseases-have-shaped-our-culture-habits-and-language-75061 [https://perma.cc/H38Y-E4E6] 
(describing how these bacterial diseases “have changed the structure and numbers of people living 
in communities”). 
 26. Tim Newman, How Do Penicillins Work?, MED. NEWS TODAY, 
https://www.medicalnewstoday.com/articles/216798.php [https://perma.cc/T5L8-8BJB].  
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streptococcal septicemia following a miscarriage.27 The success of the 
discovery provoked interest in antibiotic research, which has led to the 
development of the over 150 types of antibiotics on the market today.28 
Antibiotic drugs have greatly decreased the number of individuals 
dying from standalone bacterial diseases, and have vastly improved the 
safety of medicine.29 Antibiotics have changed the course of history by 
saving what is estimated to be hundreds of millions of lives over the 
course of the past century.30 In recognition of their great impact, the 
BBC announced in 2017 that antibiotics had been voted “Britain’s 
Greatest Invention.”31 
B. The Development of Antibiotic Resistance in Bacteria 
While current antibiotics have undoubtedly benefitted global 
health, there is still room for improvement. Regardless of the 
availability and affordability of these drugs, “[b]acterial infection 
remains a leading cause of death in both the Western and developing 
world.”32 Research on the subject suggests that multiple factors may be 
contributing to our inability to reign in infectious diseases. Chief 
among these concerns is the waning efficacy of existing antibiotics. As 
small, simple organisms with the proven ability to adapt to new 
environments and rapidly regenerate, bacteria are able to quickly 
generate new populations of stronger, better-suited pathogens when 
 
 27. John Curtis, Fulton, Penicillin and Chance, 34 YALE MED. MAGAZINE,  no. 1, 1999, 
http://ymm.yale.edu/autumn1999/features/capsule/55396 [https://perma.cc/F6PL-E92Y]; 
Newman, supra note 26. 
 28. Antibiotics, NEW MED. INFO. & HEALTH INFO., http://drugs.nmihi.com/antibiotics.htm 
[https://perma.cc/CTQ2-4TWL]. 
 29. CTRS. FOR DISEASE CONTROL & PREVENTION, ANTIBIOTIC RESISTANCE THREATS IN 
THE UNITED STATES, 2013, at 41 (2013), https://www.cdc.gov/drugresistance/threat-report-
2013/pdf/ar-threats-2013-508.pdf [https://perma.cc/Q2ZG-BHJY] (“Antibiotics were first used to 
treat serious infections in the 1940s. Since then, antibiotics have saved millions of lives and 
transformed modern medicine.”). Prior to the discovery of penicillin, women were 50 times more 
likely to die in childbirth due to infection. Which Invention Won Britain’s Greatest Invention?, 
BBC, http://www.bbc.co.uk/programmes/articles/5QRlT3MhZLnsTjrGswV2FlJ/which-
invention-won-britains-greatest-invention [https://perma.cc/ZGB2-98DX]. Penicillin also greatly 
improved the recovery rate of soldiers who incurred traumatic injuries in battle. Id. 
 30. CTRS. FOR DISEASE CONTROL & PREVENTION, supra note 29, at 41 (“Without 
[antibiotics], 200 million of us wouldn’t be here, and that’s a very conservative calculation.”). 
 31. Id.; Antibiotics Win Greatest British Invention in Live TV Broadcast, U. OXFORD MED. 
SCI. DIVISION (June 16, 2017), https://www.medsci.ox.ac.uk/news/antibiotics-win-greatest-british-
invention-in-live-tv-broadcast [https://perma.cc/DVG8-92L3]. 
 32. 77 ADVANCES IN ENZYMOLOGY & RELATED AREAS OF MOLECULAR BIOLOGY xi 
(Eric J. Toone ed., John Wiley & Sons, Inc. 2011).  
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faced with a threat.33 When that threat is an antibiotic, bacteria may 
develop ways to resist that drug.34 
Today, strains of antibiotic-resistant bacteria have emerged for 
each class of antibiotic; some of these bacteria have shown resistance 
to multiple drugs.35 Because resistance to an antibiotic drug within one 
class may confer to a bacterium some resistance to other drugs within 
the same class, this is particularly troubling.36 Infection by antibiotic-
resistant bacteria greatly limits the number of treatment options that 
are available, and the drugs that remain often have decreased efficacy, 
making it harder—and sometimes even impossible—to treat the 
infection.37 A recent report by the Center for Disease Control 
(“CDC”) estimates that at least two million people in the United States 
become infected with antibiotic-resistant bacteria each year, with 
23,000 dying as a direct result of the infection.38 By 2050, some experts 
predict that the annual number of deaths due to antibiotic-resistant 
infections will reach ten million if efforts are not made to curtail 
bacterial resistance.39 
Bacterial resistance to existing antibiotics has been further 
exacerbated by a number of factors. First, humans, and their pathogen 
hitchhikers, are able to travel faster and farther than ever before; this 
modern development has been linked to the proliferation of 
uncommon pathogenic infections in unprepared communities.40 As 
more pathogens circulate worldwide, the urbanization of modern 
 
 33. Newman, supra note 26. 
 34. Kimberly Buckmon, BARDA Seeks to Launch a Novel Partnership, a Product 
Accelerator to Address Antimicrobial Resistance, OFF. ASSISTANT SEC’Y PREPAREDNESS & 
RESPONSE: BLOG (Feb. 19, 2016), https://www.phe.gov/ASPRBlog/Lists/Posts/Post.aspx?ID=176 
[https://perma.cc/CLQ4-HXEB] (discussing the increase in and deadliness of bacterial infections 
that are resistant to existing antibiotics). 
 35. Id. 
 36. Antibiotics: An Overview, KHAN ACAD., https://www.khanacademy.org/science/health-
and-medicine/current-issues-in-health-and-medicine/antibiotics-and-antibiotic-
resistance/a/antibiotics-an-overview [https://perma.cc/N36K-CURR]. 
 37. Antibiotic Resistance, WHO (Feb. 5, 2018), http://www.who.int/mediacentre/factsheets/
antibiotic-resistance/en [https://perma.cc/U99F-UZ36]. 
 38. Antibiotic/Antimicrobial Resistance, CTRS. DISEASE CONTROL & PREVENTION (last 
updated Mar. 29, 2018), https://www.cdc.gov/drugresistance [https://perma.cc/V9U8-HH33]. 
 39. Cassandra Willyard, The Drug-Resistant Bacteria that Pose the Greatest Health Threats, 
NATURE: NEWS (Feb. 28, 2017), https://www.nature.com/news/the-drug-resistant-bacteria-that-
pose-the-greatest-health-threats-1.21550 [https://perma.cc/U5WT-ZMEC]. 
 40. See A.J. Tatem, D.J. Rogers & S.I. Hay, Global Transport Networks and Infectious 
Disease Spread, 62 ADVANCES PARASITOLOGY 293, 295 (2006) (“[T]he global growth of 
economic activity, tourism and human migration is leading to ever more cases of the movement 
of both disease vectors and the diseases they carry.”). 
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societies has created perfect conditions for a bacterial infection to 
quickly and rampantly make its way through the dense populace,41 
while the warming climate fuels the expansion of vector-borne 
diseases.42 Second, poverty, war, weakened health systems, and poor 
infrastructure all likely play a strong role in infectious disease 
outbreaks.43 
As antibiotic-resistant bacteria continue to proliferate, new 
treatments are needed to meet this growing threat. However, research 
and development (“R&D”) investments by the pharmaceutical 
industry into innovative antibiotics have been sorely lacking. Following 
the “golden” pipeline of antibiotic development in the 1960s and ‘70s, 
the majority of pharmaceutical manufacturers abandoned the field to 
pursue more lucrative therapeutics.44 Low-hanging therapies have 
already been discovered, and the costs associated with conducting 
highly intensive, complex research have risen to astronomical heights. 
As a result, by the turn of the twenty-first century, the number of new 
antibiotics in development dropped from dozens to just three.45 
The World Health Organization (“WHO”) has identified 12 
classes of pathogens that are highly resistant and thus in urgent need 
of new treatments.46 While a number of domestic and international 
 
 41. Ronak B. Patel & Thomas F. Burke, Urbanization – An Emerging Humanitarian 
Disaster, 361 NEW ENG. J. MED. 741, 741 (2009). 
 42. See Nick Watts et al., The 2017 Report of the Lancet Countdown: From 25 Years of 
Inaction to a Global Transformation for Public Health, LANCET, Oct. 2017, at 3 (identifying that 
“altered climactic conditions are contributing to growing vectorial capacity for the transmission 
of dengue fever by Aedes aegypti”).  
 43. See Waleed Al-Salem, Jennifer R. Herricks & Peter J. Hotez, A Review of Visceral 
Leishmaniasis During the Conflict in South Sudan and the Consequences for East African 
Countries, 9 PARASITES & VECTORS, Aug. 22, 2016, at 2 (“Visceral leishmaniasis . . . , also known 
as kala-azar, is a serious and often fatal neglected tropical disease . . . that is highly correlated with 
war, poverty and failed health systems . . . .”); Julia Belluz, Why is Ebola Less Deadly in America 
than in Africa?, VOX (Oct. 28, 2014), https://www.vox.com/2014/10/24/7059743/why-is-ebola-
virus-outbreak-american-africa-nina-pham [https://perma.cc/GL74-4C5N] (noting that deficient 
health care systems have led to higher rates of death from Ebola in Africa than in the United 
States). 
 44. Jose M. Munita & Cesar A. Arias, Mechanisms of Antibiotic Resistance, 4 
MICROBIOLOGY SPECTRUM, Apr. 2016, at 25; see also Ventola, supra note 11, at 279 (discussing 
that 15 of the 18 largest pharmaceutical companies have completely abandoned the antibiotic 
field).  
 45. Maryn McKenna, We Need Antibiotics. They’re Not Profitable to Make. Who Pays?, 
NAT’L GEOGRAPHIC: SCI. & INNOVATION: GERMINATION (May 23, 2015), 
http://phenomena.nationalgeographic.com/2015/05/23/oneill-amr-3 [https://perma.cc/LK76-
DNJW]. 
 46. WHO, PRIORITIZATION OF PATHOGENS TO GUIDE DISCOVERY, RESEARCH AND 
DEVELOPMENT OF NEW ANTIBIOTICS FOR DRUG-RESISTANT BACTERIAL INFECTIONS, 
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efforts have been made to incentivize pharmaceutical manufacturers 
to invest in the field,47 the vast majority of antimicrobials developed in 
conjunction with these programs are small, low-risk improvements to 
existing therapeutics.48 Only eight were identified by the WHO as 
innovative treatments that may actually add value to the current 
treatment arsenal.49 
II.  PHAGES: USING THE NATURAL ENEMY OF BACTERIA IN NEW 
TREATMENTS 
Increasing bacterial resistance and the urgent need for novel 
antimicrobial therapeutics has reignited interest within the scientific 
community about phage therapy.50 This Part introduces phages, their 
therapeutic possibilities, and some of the challenges phage therapeutic 
manufacturers face. 
A. What Are Phages? 
Phages, the most abundant biological grouping on earth, are a 
category of viruses that are able to infect bacteria.51 The term 
“bacteriophage” can be literally translated to “bacteria eater,” in 
reference to the virus’s bactericidal capabilities.52 Like most viruses, 
phages generally consist of a protein coat that surrounds a core 
 
INCLUDING TUBERCULOSIS 79 (2017), http://www.who.int/medicines/areas/
rational_use/PPLreport_2017_09_19.pdf?ua=1 [https://perma.cc/T5UE-RAYY]. The WHO’s list 
includes and prioritizes bacterial infections based on their mortality, their burden on healthcare 
systems and communities, antibiotic-resistance prevalence and trends, their transmissibility, their 
preventability, their treatability, and existing antibiotics in the pipeline. Id. at 78. The top-priority 
pathogens are strains of Pseudomonas aeruginosa, a common cause of sepsis and pneumonia; 
Enterobacteriaceae, a family of bacteria causing urinary tract and bloodstream infections and 
pneumonia; and A. baumannii, which is commonly associated with bloodstream infections and 
pneumonia. Id. at 41–42. 
 47. See infra Part IV. 
 48. Zosia Kmietowicz, Few Novel Antibiotics in the Pipeline, WHO Warns, BRIT. MED. J. 
(Sept. 19, 2017), https://www.bmj.com/content/358/bmj.j4339 [https://perma.cc/MV9N-85LJ]. 
 49. Id. 
 50. See Dwayne R. Roach et al., Synergy Between the Host Immune System and 
Bacteriophage is Essential for Successful Phage Therapy Against an Acute Respiratory Pathogen, 
22 CELL HOST & MICROBE 38, 38–39 (2017).  
 51. James MacDonald, Fighting Bacterial Infection with . . . Viruses?, JSTOR: DAILY (Apr. 
2, 2018), https://daily.jstor.org/fighting-bacterial-infection-with-viruses/ [https://perma.cc/R57G-
JX3E]. 
 52. Bacteriophage, NATURE EDUC.: SCITABLE, https://www.nature.com/scitable/definition/ 
bacteriophage-phage-293 [https://perma.cc/V83Q-5YB6] [hereinafter Bacteriophage, SCITABLE]. 
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containing viral DNA or RNA.53 While other forms exist, the most 
recognizable phage shape houses the viral genetic material in a 
spherical, twenty-sided—or icosahedral—protein shell that is 
connected by a tube to a set of spider-like legs.54  
 
As seen in Figure 1. Bacteriophage Lytic and Lysogenic Cycles,55 
phages infect their hosts by binding to a bacterium’s cell wall, 
perforating the wall through enzymatic action, and injecting viral 
genetic material into the bacterium.56 A phage’s genetic material then 
effectively “hijacks” the host cell and causes it to produce viral 
components that assemble into new phages.57 Eventually, the pressure 
of the numerous new viruses within the cell cause the infected 
bacterium to rupture and die, and the new phages burst forth to 
continue the cycle.58 This, notably, is the only method through which 
 
 53. Bacteriophage – Bacteriophage Structure, JRANK, http://science.jrank.org/pages/715/ 
Bacteriophage-Bacteriophage-structure.html [https://perma.cc/K7SG-PEDQ]. 
 54. See id. (“Bacteriophage have different three-dimensional shapes (or morphologies). T-
even phages . . . have a head that has a slightly spherical shape called an icosahedron. A tube 
connects the head to spider-like supporting legs.”).  
 55. Janis Doss et al., A Review of Phage Therapy Against Bacterial Pathogens of Aquatic and 
Terrestrial Organisms, 9 VIRUSES 50, fig. 2 (2017). 
 56. Bacteriophage – Bacteriophage Structure, supra note 53. 
 57. Bacteriophage, SCITABLE, supra note 52.  
 58. Id. (describing the process of lysis).  
Figure 1. Bacteriophage Lytic and Lysogenic Cycles. 
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phages can multiply.59 Some phages also undergo lysogenic cycles, 
whereby the phage invades a host nonlethally by injecting it with viral 
DNA that is then incorporated into the bacterial DNA and passed 
down to subsequent bacterial generations.60 Certain conditions can 
cause the dormant prophage DNA to reactivate and initiate a lytic 
cycle.61 
Like the bacteria they infect, phages can flourish in almost any 
environment,62 as they are highly adaptable.63 Researchers hypothesize 
that the coevolution of bacteria and phages has been crucial in shaping 
the microbial communities that are essential to defining life on Earth.64 
As bacteria adapt and change, phages quickly respond, keeping 
bacterial populations in check.65 This coevolution makes phages highly 
specialized to just one or a few strains of bacteria.66 While a certain 
phage strain may only be able to infect one strain of bacteria, a single 
strain of bacteria may have multiple types of phages that have adapted 
to infect it.67 Studies suggest that this relationship has led to a vast 
continuum of genetic variation in the phage world.68  
Because the continued existence of a specific phage strain is 
conditioned on phages of those type finding a proper bacterial host, 
phages targeted to infecting specific strains of bacteria are found 
 
 59. See Beata Weber-Dabrowska et al., Bacteriophage Procurement for Therapeutic 
Purposes, 7 FRONTIERS MICROBIOLOGY, Aug. 12, 2016, at 2 (“Bacteriophages are viruses which 
have the ability to multiply only in bacterial cells . . . .”).  
 60. Bacteriophages, KHAN ACAD., https://www.khanacademy.org/science/biology/biology-
of-viruses/virus-biology/a/bacteriophages [https://perma.cc/PDR8-2S28]. 
 61. Id.  
 62. Howard Hughes Med. Inst., Understanding Genetic Diversity of Bacteriophage, 
PHYS.ORG (Apr. 29, 2015), https://phys.org/news/2015-04-genetic-diversity-bacteriophages.html 
[https://perma.cc/SC4V-M8U3]. 
 63. Britt Koskella & Michael A. Brockhurst, Bacteria-Phage Coevolution as a Driver of 
Ecological and Evolutionary Processes in Microbial Communities, 38 FEMS MICROBIOLOGY 
REV. 916, 924 (2014). 
 64. Id. at 920.  
 65. Id. at 923. 
 66. Id. at 925 (discussing the coevolution of phages and bacteria, the variety of phage 
genotypes it produces, and suggesting that this genetic mosaicism means there is “some constraint 
upon host range even among the most broadly infectious phages”). 
 67. Julianne H. Grose & Sherwood R. Casjens, Understanding the Enormous Diversity of 
Bacteriophages: The Tailed Phages that Infect the Bacterial Family Enterobacteriaceae, 
VIROLOGY, Sept. 19, 2014, at 421–22.  
 68. See Howard Hughes Med. Inst., supra note 62 (“The study compared the genomes of 627 
bacteriophages isolated from a single species of bacteria, and found a continuum of genetic 
diversity, rather than discrete groups within the population.”). 
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wherever that bacterium is.69 For example, phages exist as highly 
specified and highly effective killers in lakes, soil, sludge, fecal matter, 
and other bacteria-rich environments.70 Human-altered environments, 
such as areas with hospital waste and sewage, therefore offer rich 
supplies of phages that are capable of infecting bacteria that are 
pathogenic in humans.71 
B. Developing Therapeutic Interventions that Utilize Phages 
After phages were officially discovered in the early twentieth 
century, scientists quickly identified their possible therapeutic 
potential.72 In 1917, approximately one year after the first phages were 
isolated, microbiologist Felix d’Herelle tested a phage cocktail on a 
number of patients suffering from severe dysentery.73 All four patients 
recovered within 24 hours after receiving a single dose of phages.74 By 
the 1940s, several companies had begun developing and producing 
phage therapies targeted at bacterial pathogens such as staphylococci, 
streptococci, and Escherichia coli.75  
Despite some initial success, the efficacy of these early phage 
therapeutics remained controversial within the scientific community.76 
Around the same time, antibiotics came bursting onto the scene with 
the discovery of penicillin.77 Not long afterwards, the Western world 
 
 69. See Dipali Pathak, Bacteriophages, Natural Drugs to Combat Superbugs, PHYS.ORG 
(Apr. 18, 2017), https://phys.org/news/2017-04-bacteriophages-natural-drugs-combat-
superbugs.html [https://perma.cc/2W9F-3YSM] (noting that birds and dogs carrying a particular 
Escherichia coli bacteria strain also carry the phages specific to that strain).  
 70. Weber-Dabrowska et al., supra note 59, at 2, 6. 
 71. Roja Rani Pallavali et al., Isolation and In Vitro Evaluation of Bacteriophages Against 
MDR-Bacterial Isolates from Septic Wound Infections, 12 PLOS ONE, July 18, 2017, at 3, 
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179245 [https://perma.cc/ 
475C-EMG7]. 
 72. See Alexander Sulakvelidze, Zemphira Alavidze & J. Glenn Morris, Jr., Bacteriophage 
Therapy, 45 ANTIMICROBIAL AGENTS & CHEMOTHERAPY 649, 649–50 (2001) (discussing the 
official discovery of phages by Felix d’Herelle and his subsequent use of phages to treat dysentery 
in 1919).  
 73. Zhabiz Golkar, Omar Bagasra & Donald Gene Pace, Bacteriophage Therapy: A Potential 
Solution for the Antibiotic Resistance Crisis, 8 J. INFECTION DEVELOPING COUNTRIES 129, 131 
(2014). 
 74. Id. 
 75. Sulakvelidze et al., supra note 72, at 650. 
 76. Id.  
 77. Id.; Newman, supra note 26. 
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abandoned its pursuit of effective phage therapeutics in favor of these 
easier-to-produce, cheaper, and more consistent drugs.78  
1. Creating Phage-Based Therapeutic Products.  With the 
potentially catastrophic effects of antibiotic resistance looming in the 
near future, physicians’ and researchers’ interests in phage therapy 
have been reinvigorated.79 Mr. Patterson’s sensational story is just one 
example of the scientific community testing the waters of phage 
therapeutics.80 Phage therapies present a number of observed and 
theoretical benefits over traditional antibiotics. Unlike antibiotics, 
bacterial resistance to phages is not generally a threat; even the 
toughest multidrug-resistant bacteria are fully vulnerable to the right 
phage.81 If a bacterial strain exposed to phage therapy does develop 
some defense mechanism against phage infection, true resistance is 
unlikely to develop.82 Unlike the static chemical compounds that make 
up antibiotics, phages are living things. As naturally occurring 
organisms with many millennia of natural selection ingrained in their 
evolutionary past, phages likely have the innate ability to counter 
almost any phage-resistant bacterial adaptations.83 This would allow 
physicians to alter phage treatments in real time to kill bacteria, should 
resistance develop.84  
Unlike traditional antibiotics that may target and destroy good or 
neutral systemic bacteria, phages are also highly specified to certain 
 
 78. Sulakvelidze et al., supra note 72, at 650. Some research on, and therapeutic use of, 
phages continued in a number of Eastern European countries and the Soviet Union; this work 
has yielded a fair amount of international literature supporting the safety and efficacy of various 
phage therapies. Id.  
 79. See LaFee & Buschman, supra note 2 (describing the possibilities of phage therapy for 
multidrug-resistant infections and personalized medicine).  
 80. See Carl Zimmer, A Virus, Fished Out of a Lake, May Have Saved a Man’s Life – And 
Advanced Science, STAT (Dec. 7, 2016), https://www.statnews.com/2016/12/07/virus-bacteria-
phage-therapy/ [https://perma.cc/B2UL-EPDF] (describing another successful use of phage 
therapy in the United States). 
 81. See Joanna Urban, Advancing Phage Therapy, AM. SOC’Y MICROBIOLOGY: 
MBIOSPHERE (Jan. 17, 2017), https://www.asm.org/index.php/mbiosphere/item/5471-advancing-
phage-therapy [https://perma.cc/332W-2ZNP] (“Antibiotic-resistant bacteria are usually fully 
sensitive to phages, and because phages are so abundant in nature, multiple phages can be used 
together or combined with antibiotics to maximize treatment outcomes.”). 
 82. Golkar et al., supra note 73, at 131. However, that is not to say that a specific strain of 
bacteria cannot become fully resistant to a specific phage strain.  
 83. See id. (“Like bacteria, phages mutate and therefore can evolve to counter phage-
resistant bacteria.”). 
 84. See Pathak, supra note 69 (quoting a scientist working with phages: “Should resistance 
develop again, we will evolve another phage - right back at them!”). 
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hosts, which limits their ability to bind to off-target sites.85 This makes 
them particularly safe therapeutics, with low toxicity and a much lower 
risk of negative side effects than traditional antibiotics.86 The relatively 
benign systemic effects of phages on humans allow physicians to safely 
combine multiple phage strains into therapeutic cocktails when it is 
unclear which strain will be effective against a certain bacterium, or 
when doing so will synergistically increase the strength of the therapy.87 
Finally, a particularly salient strength of phage therapeutics is the 
mechanism by which they kill bacteria. Because phages destroy 
bacterial cells by reproducing within them, the therapeutic agent itself, 
the phage, multiplies at the site of the infection, thus concentrating and 
strengthening the treatment where it is needed most.88 
2. Biotechnology Companies Currently Researching Phage 
Therapies.  Reinvigorated interest in phage therapy has prompted both 
governmental bodies and a few private biotechnology companies to 
begin investigating phage therapeutics. In the United States, the 
National Institute of Allergy and Infectious Diseases (“NIAID”) has 
identified phage therapy as one of seven prongs in its plan to combat 
antibiotic resistance, and has awarded grants to a number of 
universities studying phage therapies.89 Although no phage 
therapeutics are currently approved for use in humans in the United 
States, the Food and Drug Administration (“FDA”) announced in 
2017 that it will allow compassionate use.90 The European Commission 
expressed its approval in 2014 by funding Phagoburn, the first large, 
 
 85. Golkar et al., supra note 73, at 131. 
 86. Weber-Dabrowska et al., supra note 59, at 2. 
 87. See id. at 3. Studies have recorded synergistic effects when combining multiple phages 
that are each effective against the same host. Id. 
 88. Id. at 2.  
 89. Sara Reardon, Phage Therapy Gets Revitalized, NATURE: NEWS (June 3, 2014), 
https://www.nature.com/news/phage-therapy-gets-revitalized-1.15348 [https://perma.cc/3UL9-
UJJP]; Press Release, Nat’l Inst. Health, New NIH Awards Will Support Development of 
Therapeutic Alternatives to Traditional Antibiotics (Jan. 12, 2016) [hereinafter New NIH 
Awards], https://www.nih.gov/news-events/news-releases/new-nih-awards-will-support-
development-therapeutic-alternatives-traditional-antibiotics [https://perma.cc/Z9P6-4H9B]. 
 90. Julie Odland, Everything Old is New Again: Bacteriophage Therapy, CLARIVATE 
ANALYTICS (Dec. 14, 2017), https://clarivate.com/blog/life-sciences-connect/everything-old-new-
bacteriophage-therapy/ [https://perma.cc/Z433-VXQB]. “Compassionate use” refers to the use of 
investigational, non-FDA-approved therapeutic products for treatment purposes; it is generally 
only available in serious or life-threatening situations when all available treatment options have 
been exhausted. Expanded Access (Sometimes Called Compassionate Use), U.S. FOOD & DRUG 
ADMIN., https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionate
Use/default.htm [https://perma.cc/YR3C-MQNU] (last updated June 19, 2018). 
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multicenter, multiyear clinical trial testing phage therapies for human 
infections.91 
Three private sector companies have taken the lead in 
investigating phage therapeutics in the United States. While not geared 
toward treating bacterial infections, Intralytix has brought to market a 
number of FDA-approved phage products that address food safety 
issues.92 On February 15, 2018, Intralytix announced that the FDA 
cleared Intralytix’s phage treatment for Crohn’s disease for Phase I/II 
clinical trials, making it one of the first phage therapies to begin clinical 
testing in the United States.93 Another company, AmpliPhi 
Biosciences, was on the team that helped treat Tom Patterson.94 
AmpliPhi is currently developing multiphage therapeutics aimed at 
treating infections caused by Staphylococcus aureus and Pseudomonas 
aeruginosa, both of which are on the WHO’s 2017 Priority Pathogens 
List.95 Finally, EpiBiome has developed and brought to market a 
superior bacterial profiling service,96 and has developed partnerships 
with a number of organizations to leverage this technology in 
developing highly targeted phage therapeutics.97  
While these ongoing efforts suggest a percolating interest in phage 
therapeutics, progress and investment in the field remains minimal in 
Western countries. 
3. Challenges in Developing Phage Therapeutics.  The road to 
creating phage therapeutics is not smoothly paved, and many 
 
 91. Reardon, supra note 89.  
 92. Frequently Asked Questions, INTRALYTIX, http://www.intralytix.com/
index.php?page=faq [https://perma.cc/CBC8-D5AP].  
 93. Intralytix Receives FDA Clearance to Initiate Phase I/IIa Clinical Trials, INTRALYTIX 
(Feb. 15, 2018), http://www.intralytix.com/index.php?page=news&id=87 [https://perma.cc/
6WLE-835P]. 
 94. Marlene Cimons, This Man Should Have Died, But Unusual Infusions Saved His Life, 
WASH. POST (July 2, 2017), https://www.washingtonpost.com/national/health-science/this-man-
should-have-died-but-unusual-infusions-saved-his-life/2017/06/30/503585b6-4aec-11e7-9669-
250d0b15f83b_story.html?utm_term=.7fa3b6edc736 [https://perma.cc/4SEP-2REJ]. 
 95. Pipeline, AMPLIPHI BIOSCIENCES CORP., http://www.ampliphibio.com/pipeline/ 
[https://perma.cc/F4GB-KWH6]. 
 96. See Bacterial Profiling: Why Do We Need to Profile Bacteria?, EPIBIOME, 
https://www.epibiome.com/products-services/bacterial-profiling/ [https://perma.cc/VQ58-R4A8] 
(describing this profiling service as “breakthrough technology that enables the most reliably 
accurate biogram results”). 
 97. Phage Based Technologies: What Are Bacteriophages?, EPIBIOME, 
https://www.epibiome.com/products-services/phage-based-technologies/ [https://perma.cc/
AMW2-GLYQ]. 
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challenges stand in the way of companies developing these products. 
As previously mentioned, the adaptability of phages has produced a 
great variety of phages in the natural world.98 Sifting through this vast 
number of phages to identify a strain capable of targeting a specific 
pathogen involves significant time, effort, and collaboration.99 Further 
complicating phage screening and selection are the instability of certain 
phage strains when in isolated storage, as well as the risk of a strain 
having lysogenic capabilities that can transfer genetic information that 
dangerously alters bacterial virulence or resistance.100 Phage-based 
product developers also face a number of manufacturing challenges 
when isolating, culturing, purifying, sterilizing, preparing, and storing 
phages.101 Phage purification and sterilization are particularly delicate 
tasks. Because phages must be cultured within bacteria, the resulting 
products must be thoroughly filtered to remove any remnants of 
hazardous bacterial endotoxins.102 The manufacturing expenses for 
phage products likely match the high costs seen elsewhere in the 
pharmaceutical industry.103  
Importantly, phage products are subject to arguably ill-suited 
FDA regulation.104 The clinical trials required by the FDA will likely 
be complicated by the immediacy with which treatment is often 
required for bacterial infections, the degree of specificity required 
 
 98. See Mikael Skurnik, Maria Pajunen & Saija Kiljunen, Biotechnological Challenges of 
Phage Therapy, 29 BIOTECHNOLOGY LETTERS 995, 1001 (2007) (reporting a high rate of genetic 
novelty among phages sequenced as part of a study of the extensive mosaicism of phage genomes); 
see also supra Part II.A. 
 99. About, PHAGE DIRECTORY, https://phage.directory/about [https://perma.cc/Z5M6-
AQAV].  
 100. See Hans-W. Ackermann, Denise Tremblay & Sylvain Moineau, Long-Term 
Bacteriophage Preservation, WORLD FED’N FOR CULTURE COLLECTIONS NEWSL., Issue no. 38, 
Jan. 2004 (noting difficulties in the long-term storage of phages); Franklin L. Nobrega, Ana Rita 
Costa, Leon D. Kluskens & Joana Azeredo, Revisiting Phage Therapy: New Applications for Old 
Resources, 23 TRENDS MICROBIOLOGY 185, 185–86 (2015) (noting lysogenic capabilities that risk 
transferring new genes to bacteria). 
 101. See Stephen T. Abedon, Sarah J. Kuhl, Bob G. Blasdel & Elizabeth Martin Kutter, Phage 
Treatment of Human Infections, 1 BACTERIOPHAGE 66, 74, 81 (2011) (describing some steps of 
the phage manufacturing process). 
 102. Skurnik et al., supra note 98, at 999.  
 103. See Catherine Loc-Carrillo & Stephen T. Abedon, Pros and Cons of Phage Therapy, 1 
BACTERIOPHAGE 111, 113 (2011) (“Generally these costs of phage production, per unit, are not 
out of line with the costs of pharmaceutical production while the costs of discovery (isolation) and 
characterization can be relatively low.”). 
 104. Callum J. Cooper, Mohammadali Khan Mirzaei & Anders S. Nilsson, Adapting Drug 
Approval Pathways for Bacteriophage-Based Therapeutics, 7 FRONTIERS MICROBIOLOGY, Aug. 
2016, at 11.  
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when matching a phage product and a bacterial strain, comorbidities, 
and the small number of patients that suffer from the most aggressive 
antibiotic-resistant bacterial infections.105 Furthermore, one of the 
biggest strengths of phage-based products is the potential to create 
precision cocktails or to adapt a cocktail to target an adapting 
bacterium.106 It remains unclear whether each altered cocktail would 
require full FDA approval as a new therapeutic product.107 Acquiring 
FDA approval in advance for each individual phage that may be used 
in a cocktail would also be prohibitively expensive, as phage libraries 
can include thousands of distinct phages.108 While the FDA has 
indicated an interest in addressing these regulatory challenges, the 
status of the regulatory pathway for phage therapeutics remains 
unclear.109 
III.  THE PATENTABILITY OF PHAGE THERAPIES 
It has long been understood that the unique economic 
characteristics of the pharmaceutical industry are largely to blame for 
the exceedingly high price associated with bringing a new drug to 
market.110 Though there is heated debate surrounding the issue, most 
scholars estimate the cost of developing a new drug to be between $1.5 
and $2.6 billion.111 The two factors that have emerged as particularly 
responsible for the high cost of drug development are the expense of 
clinical testing and the high risk of product failure.112  
To offset R&D costs, patent protection and other regulatory 
exclusivities have proven to be highly important for incentivizing 
 
 105. Id. at 2. 
 106. See supra Part II.B.1. 
 107. Cooper et al., supra note 104, at 6.  
 108. Id. 
 109. See AmpliPhi Biosciences Provides Corporate and Strategic Update, BUS. WIRE (Dec. 14, 
2017), https://www.businesswire.com/news/home/20171214006331/en/AmpliPhi-Biosciences-
Corporate-Strategic-Update [https://perma.cc/2EZW-TK26] (stating that the FDA has 
“expressed a commitment to addressing the unique regulatory challenges that might arise during 
product development”). 
 110. Iain Cockburn & Genia Long, Editorial, The Importance of Patents to Innovation: 
Updated Cross-Industry Comparisons with Biopharmaceuticals, 25 EXPERT OPINION ON 
THERAPEUTIC PATS. 739, 740 (2015).  
 111. Rachel E. Sachs, Innovation Law and Policy: Preserving the Future of Personalized 
Medicine, 49 U.C. DAVIS L. REV. 1881, 1889 n.28 (2016).  
 112. Cockburn & Long, supra note 110, at 739.  
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pharmaceutical innovation.113 Patents and other types of exclusivity 
allow pharmaceutical manufacturers to extract significant value from 
their inventions by granting a limited monopoly during which 
competition is prohibited and pricing is discretionary.114 Extracting 
sufficient profits from a product during this initial period of exclusivity 
is highly important to pharmaceutical manufacturers, as an innovator 
drug’s share of market sales drops to near nothing as soon as a less 
expensive, generic version is introduced.115 This dynamic has caused 
patents to become highly valued in the pharmaceutical industry.116 
Numerous studies provide empirical support for the importance of 
commercial exclusivities in pharmaceuticals; they report that patents 
are used more often, that they are more heavily relied on, and that they 
are considered more valuable for innovation in the pharmaceutical 
industry than in other comparable industries.117 Many statutory 
schemes, such as the Drug Price Competition and Restoration Act of 
1984, rely heavily on patent rights to encourage drug manufacturers to 
take on challenging R&D by providing a means for them to recoup 
those costs in the market.118 
A. The Problem of Weak Patent Protection for Phage Therapies 
Dubious or categorically excluded patent protection for phage 
therapies could have highly negative implications for the development 
of phage therapeutics. Because of the unique challenges associated 
with developing phage-based therapies, the cost associated with 
bringing a phage therapy to market is likely to match, if not exceed, the 
multibillion-dollar price tag associated with bringing a new small-
molecule drug to market.119 As previously discussed, phages are 
numerous, highly variable, highly specialized, and unlikely to traipse 
smoothly through the FDA’s existing regulatory pathway.120 Bacteria 
 
 113. See id. (explaining that R&D must be funded by profits from successful, on-market 
medicines and that typically, once patent protection lapses, generics launch and their share-value 
increases). 
 114. Frederick M. Abbott, Excessive Pharmaceutical Prices and Competition Law: Doctrinal 
Development to Protect Public Health, 6 U.C. IRVINE L. REV. 281, 286–87 (2016). 
 115. Cockburn & Long, supra note 110, at 740. One study suggests that an innovator drug’s 
market share drops to about 16 percent within a year of generic entry. Id. 
 116. Id. at 739. 
 117. Id. at 740–41. 
 118. Id.  
 119. See supra Part II.B.3. 
 120. See supra Parts II.A, B.3. 
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can also mutate quickly, meaning there is a risk of a specific phage 
therapy that is invested in today being rendered worthless tomorrow.121 
While one of the strengths of phages is that they can evolve to meet 
bacterial resistance, the regulatory roadblocks discussed supra in Part 
II.B.3 present a challenge for addressing this resistance in real time.  
Bringing new treatments for bacterial infections to market 
involves an additional set of challenges for developers that are not as 
prevalent for developers of drugs targeting other diseases or illnesses. 
Bacterial infections lack a strong array of diagnostics that are able to 
quickly and cost-effectively identify specific pathogenic infections 
against which an antimicrobial can be tested.122 Because bacterial 
infections often require immediate treatment, the lack of good 
diagnostic options would likely complicate and lengthen the already 
extensive clinical trial process by making it more difficult to identify 
proper participants and control for confounding factors.123 
Antimicrobials are also taken only for short periods of time and 
therefore generate a smaller volume of sales than treatments for 
chronic conditions.124 Those sales are unlikely to be recoupable 
through high prices due to the public perception associating the 
historically high prevalence and low costs of antibiotics with low 
value.125 Sales of new antibiotics are further inhibited by medical and 
public health policies that encourage the sparing use of newer 
antibiotics to preserve their novelty in order to delay the development 
of resistance.126 Insufficiently protecting the front end investment of 
phage product developers may discourage interest, investment, and 
innovation in the field.127 
 
 121. See Andrej Godány, Gabriela Bukovská, Jarmila Farkašovská & Ivan Mikula, Phage 
Therapy: Alternative Approach to Antibiotics, 58 BIOLOGIA 313, 316 (2003) (explaining how 
bacterial strains develop phage resistance and outlining five groups of bacterial resistance). 
 122. GREGORY W. DANIEL ET AL., DUKE-MARGOLIS CTR. HEALTH POL’Y, TRACKING THE 
PROGRESS OF ECONOMIC INCENTIVES FOR ANTIMICROBIAL DRUG DEVELOPMENT IN THE U.S. 
AND ACROSS THE GLOBE 6 (2016), https://healthpolicy.duke.edu/sites/default/files/atoms/files/
Antimicrobial%20Economic%20Incentives%20Landscape%20Analysisv2.pdf [https://perma.cc/
DPB6-6D2K]. 
 123. Id.  
 124. Id. at *6–7. 
 125. See Ventola, supra note 11, at 279 (“Newer antibiotics are generally priced at a maximum 
of $1,000 to $3,000 per course compared with cancer chemotherapy that costs tens of thousands 
of dollars. The availability, ease of use, and generally low cost of antibiotics has . . . led to a 
perception of low value among payers and the public.”). 
 126. Id. at 279–80. 
 127. See supra Part II.B.3. 
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Patents also play an important role in signaling value to potential 
investors.128 Removing that signal may therefore decrease the funding 
opportunities available to companies developing phage therapies to 
finance their expensive R&D. Intralytix, one of the most active 
patentees in phage therapy, has already demonstrated the value of 
their existing portfolio by securing a single investment worth over $17 
million.129 
Failing to properly protect phage therapy patents could have far-
reaching implications outside of the field as well. Low levels of 
innovation may lead to developers abandoning the field as in the 1940s; 
even if developers stay in the market, lack of competition may inhibit 
competitive innovation and pricing, or may facilitate the development 
of natural monopolies that can perpetually charge monopoly prices. 
Without the guarantee of patent protection, fewer second-comers will 
be incentivized to enter the market, and competitive pricing will falter. 
As concerns about healthcare spending in the United States become 
increasingly panicked, physicians may be hesitant to prescribe 
expensive phage therapies when traditional antibiotics are currently—
and have historically been—so inexpensive.130 Similar concerns could 
discourage insurance companies from covering such treatments. 
Discouraging the use of alternative antibiotics like phages could have 
the unfortunate effect of exacerbating antibiotic resistance. 
B. Mayo, Myriad, and the Changing Patent Landscape 
The patentability of phage therapeutics has been called into 
question by a number of recent cases that have cast doubt on the 
patentability of many life sciences products, and have thrown the 
industry into chaos.131 In the first of these cases, Mayo Collaborative 
 
 128. Hanna Hottenrott, Bronwyn H. Hall & Dirk Czarnitzki, Patents as Quality Signals? The 
Implications for Financing Constraints on R&D, 25 J. ECON. INNOVATION & NEW TECH. 197, 199 
(2016).  
 129. Lesaffre Invests in Intralytix, a US Biotechnology Company, PRNEWSWIRE (July 24, 
2017), https://www.prnewswire.com/news-releases/lesaffre-invests-in-intralytix-a-us-
biotechnology-company-300493121.html [https://perma.cc/4QUP-73BR]. 
 130. See Carolyn Y. Johnson, The U.S. Spends More on Health Care than Any Other Country. 
Here’s What We’re Buying, WASH. POST (Dec. 27, 2016), https://www.washingtonpost.com/
news/wonk/wp/2016/12/27/the-u-s-spends-more-on-health-care-than-any-other-country-heres-
what-were-buying/?utm_term=.4d15fcd5c03e [https://perma.cc/YRR5-S5QL] (discussing the 
mounting concerns with high levels of health care spending in the United States). 
 131. Arti K. Rai & Jacob S. Sherkow, The Changing Life Science Patent Landscape, 34 
NATURE BIOTECHNOLOGY 292, 292 (2016). 
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Services v. Prometheus Laboratories, Inc.,132 the Supreme Court held 
invalid a patent claiming a method of determining the proper dosage 
of a thiopurine drug.133 Depending on how a patient metabolizes 
thiopurine drugs, the same dose may be too high and risk harmful side 
effects in one patient, while being too low, and likely ineffective, in 
another.134 The relevant patent addressed this difficulty in dosing by 
claiming a method of measuring the concentration of two known 
metabolites of thiopurine in a patient’s blood, and comparing them to 
specified maximum and minimum threshold values in order to 
determine the proper dosage.135 
The statute at issue in Mayo, 35 U.S.C. § 101, defines the 
parameters of patentable subject matter as including the invention or 
discovery of “any new and useful process, machine, manufacture, or 
composition of matter, or any new and useful improvement thereof.”136 
However, the Court acknowledged a longstanding exception to § 101 
that excludes “laws of nature, natural phenomena, and abstract ideas” 
from inclusion as patent-eligible subject matter.137 The Court in Mayo 
analyzed whether the patent claims at issue fell under the first 
exclusion category as a “law of nature.” Looking first at the correlation 
between the concentration of metabolites and the likelihood of over- 
or underdosage, the Court found the relationship to be unpatentable 
as a “natural law.”138 The correlation, argued the Court, concerns “the 
ways in which thiopurine compounds are metabolized by the body—
entirely natural processes.”139 The Court then considered whether the 
patent claims did “significantly more than simply describe these natural 
relations,” or whether the application of the law of nature in the 
claimed method was sufficiently transformative.140 The Court found 
that the claimed application of the law—having a physician “first 
administer a thiopurine drug and [then] measure the resulting 
metabolite concentrations” to determine proper dosage—constituted 
no more than an instruction to use the “well-understood, routine, 
conventional activit[ies] already engaged in by the scientific 
 
 132. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012). 
 133. Id. at 77. 
 134. Id. at 73. 
 135. Id. at 73–74. 
 136. 35 U.S.C. § 101 (2012). 
 137. Mayo, 566 U.S. at 70 (quoting Diamond v. Diehr, 447 U.S. 175, 185 (1981)). 
 138. Id. at 77. 
 139. Id. 
 140. Id. 
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community,” by which a physician would normally utilize such a law.141 
The Court therefore held that the claimed application lacked a 
sufficiently inventive step.142 
The life sciences were dealt another blow the next year by the 
Supreme Court’s unanimous decision in Association for Molecular 
Pathology v. Myriad Genetics, Inc.143 Prior to that litigation, Myriad 
identified and patented the sequences of the BRCA1 and BRCA2 
genes, in which are found mutations linked to higher risks of breast and 
ovarian cancers.144 The challenged patents covered sequences of parts 
of the genes’ isolated DNA and “cDNA”—a synthetic type of DNA 
that is created in a lab.145 Unlike naturally occurring DNA, cDNA is 
manufactured to include only the portions of the targeted genetic 
sequence that code for proteins, with the naturally interspersed 
noncoding regions removed.146 The Myriad Court analyzed whether 
the patent claims fell under the second exclusion category as a “natural 
phenomena,” that is, whether they claimed a product of nature. 
Beginning its § 101 analysis with the claims covering isolated genetic 
DNA, the Court explained that the company “did not create anything” 
new by identifying and isolating the BRCA sequences.147 The BRCA 
DNA sequence exists as is in nature, and as such was found to be 
unpatentable.148 Unlike genomic DNA, however, cDNA is man-made; 
the Court explained that cDNA is therefore distinct from DNA 
because “something new” is created when a laboratory technician 
produces a DNA product with the noncoding regions removed.149 As 
such, cDNA was found to be patent-eligible.  
The final case that largely reshaped patentability under § 101 was 
Alice Corp. v. CLS Bank International,150 which considered the 
patentability of a computer program under § 101’s third judicial 
exception for “abstract ideas.”151 In Alice, the Supreme Court refined 
and solidified its test for patent subject-matter eligibility under § 101 
 
 141. Id. at 79–80. 
 142. Id.  
 143. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013). 
 144. Id. at 583. 
 145. Id. at 580, 582. 
 146. Id. at 582. 
 147. Id. at 590–91. 
 148. Id.  
 149. Id. at 594–95. 
 150. Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347 (2014). 
 151. Id. at 2354. 
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into a two-step framework that has become known as the “Mayo/Alice 
test.” According to January 2018 guidance from the U.S. Patent and 
Trademark Office (“USPTO”) on patentable subject matter, the 
Mayo/Alice test first requires determining whether a patent claim is 
within a judicial exception, that is, whether the claim is “directed to a 
law of nature, a natural phenomenon (product of nature) or an abstract 
idea.” If so, then a court must determine whether the claim is 
nevertheless entitled to patent protection because it involves an 
inventive concept, that is, whether “the claim recite[s] additional 
elements that amount to significantly more than the judicial 
exception.”152  
Neither the relevant industries nor the lower courts have received 
the Mayo/Alice test favorably. Major concerns are percolating in the 
life sciences sector over future patent eligibility153 as the U.S. Court of 
Appeals for the Federal Circuit struggles to understand the Court’s 
broad, abstruse test.154 Applications of the test following Alice have 
largely favored ineligibility, with over 90 percent of post-Alice Federal 
Circuit decisions on the issue finding patent ineligibility under Mayo, 
Myriad, and Alice, as of March 2017.155 In Ariosa Diagnostics, Inc. v. 
Sequenom, Inc.,156 the Federal Circuit applied the Mayo/Alice test to 
invalidate a patent claiming a method of amplifying and detecting 
paternally inherited cell-free fetal DNA located in a sample of a 
 
 152. U.S. PAT. & TRADEMARK OFF., MPEP § 2106 (9th ed. Rev. 08.2017, Jan. 2018). While it 
was initially thought that Alice might be limited to software patents, the Federal Circuit validated 
its applicability to the life sciences by invoking the test in subsequent biotechnology cases. 
Douglas Hallward-Driemeier, Federal Circuit Applies Alice to Biotechnology in Striking Down 
Myriad Method of Screening Claims, Leaves Door Open for Narrower Method Claims, ROPES & 
GRAY: NEWSROOM (Dec. 18, 2014), https://www.ropesgray.com/en/newsroom/alerts/2014/
December/Federal-Circuit-Applies-Alice-to-Biotechnology-in-Striking-Down-Myriad-Method-
of-Screening-Claims [https://perma.cc/6VMW-P46W]. 
 153. Robert L. Stoll, New Patent Subject-Matter Eligibility Test Hurts US Competitiveness, 
THE HILL (Jan. 27, 2016), http://thehill.com/blogs/pundits-blog/technology/267139-new-patent-
subject-matter-eligibility-test-hurts-us [https://perma.cc/EQG3-WT92]. 
 154. See Steven M. Amundson, The Supreme Court’s Decision in Alice Corp. v. CLS Bank 
Has Taken a Heavy Toll on Patents for Computer-Related Inventions, LEXOLOGY (Feb. 16, 2016), 
https://www.lexology.com/library/detail.aspx?g=300e6862-012d-49dd-bed4-ba8ae4477397 
[https://perma.cc/TL5W-BMQT] (“Absent clear guidance from the Supreme Court, lower courts 
have at times had difficulty determining what constitutes an abstract idea and what amounts to 
an inventive concept.”). 
 155. David Kappos, Dir., U.S. Pat. & Trademark Off. 2009–2013, Address at the Federal 
Circuit Bar Association & the Center for Innovation Policy at Duke Law Symposium: Are Patents 
Under Attack? 9 (Apr. 6, 2018) (PowerPoint slides on file with Duke Law Journal).  
 156. Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015). 
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pregnant woman’s circulating blood.157 Though the court agreed that 
the discovery “revolutionized prenatal care” by establishing a 
noninvasive means of detecting genetic conditions of a fetus,158 the 
court found the method was not an inventive application of a law of 
nature under the Mayo/Alice test because the methods of fractioning 
blood and amplifying and detecting nucleic acid are “routine, 
conventional techniques.”159 The Federal Circuit used similar 
reasoning in 2016 to invalidate the patent at issue in Genetic 
Technologies Ltd. v. Merial L.L.C.,160 which claimed a method of 
detecting a coding region of an individual’s DNA by amplifying and 
analyzing linked noncoding regions.161 
The courts have invalidated a number of other diagnostic and 
method of treatment patents in the wake of Mayo, Myriad, and Alice. 
Examples include patents claiming a method of treating patients with 
inhaled nitric oxide in a way that decreases the risk of pulmonary 
edema,162 patents claiming a method for determining whether a 
particular type of drug is likely to be effective based on the presence or 
absence of certain genetic mutations,163 and patents covering a method 
of diagnosing cardiovascular risk by detecting and analyzing the levels 
of a specific enzyme in a biological sample.164 
Composition of matter claims have also fared poorly under the 
Mayo/Alice test. In Natural Alternatives International, Inc. v. Creative 
Compounds, L.L.C.,165 the U.S. District Court for the Southern District 
of California considered patents claiming a dietary supplement 
comprised of the amino acid beta-alanine.166 The court found that the 
claims were actually directed to beta-alanine itself, a naturally 
occurring phenomenon.167 As such, even isolated in the form of a 
 
 157. Id. at 1373–74. 
 158. Id. at 1379 (quoting Brief of Appellant at 25, Ariosa Diagnostics, Inc. v. Sequenom, Inc., 
788 F.3d 1371 (Fed. Cir. 2015) (Nos. 2014-1139, 2014-1144)). 
 159. Id. at 1377 (citing 35 U.S.C.A. § 101 (2012)). 
 160. Genetic Techs. Ltd. v. Merial L.L.C., 818 F.3d 1369 (Fed. Cir. 2016). 
 161. Id. at 1372. 
 162. Mallinckrodt Hosp. Prods. IP Ltd. v. Praxair Distribution, Inc., No. 15-170-GMS, 2017 
WL 3867649, at *2 (D. Del. Sept. 5, 2017). 
 163. Esoterix Genetic Labs. LLC v. Qiagen Inc., 133 F. Supp. 3d 349, 351–52 (D. Mass. 2015).  
 164. Cleveland Clinic Found. v. True Health Diagnostics LLC, 859 F.3d 1352, 1355 (Fed. Cir. 
2017).  
 165. Nat. Alternatives Int’l, Inc. v. Creative Compounds, LLC, Nos. 16-cv-02146-H-AGS, 16-
cv-02343-H-AGS, 2017 WL 3877808 (S.D. Cal. Sept. 5, 2017). 
 166. Id. at *5.  
 167. Id.  
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supplement, the claims were directed at a patent-ineligible product of 
nature.168 Because placing a natural substance into a dietary 
supplement and administering it to an individual to achieve a 
therapeutic effect is a conventional activity, the claims also failed under 
step two, the inventive concept prong, of the Mayo/Alice test.169  
Life sciences companies are not completely without hope, 
however. A few months after Merial, the Federal Circuit upheld a 
patent in Rapid Litigation Management Ltd. v. CellzDirect, Inc.170 that 
claimed a method of producing liver cells that remain viable following 
multiple cryopreservations using density gradient fractionation.171 The 
court’s decision was based on its finding that the claim was directed not 
at the natural law defining liver cells’ ability to survive multiple freeze-
thaw cycles, but rather at a “new and useful laboratory technique for 
preserving [liver cells].”172 The court went on to explain that the claim 
would succeed under the Mayo/Alice test’s second step regardless 
because while the “individual steps of freezing and thawing were well 
known,” the process of repeating those steps to preserve liver cells for 
multiple cycles was, as a whole, “far from routine and conventional.”173  
CellzDirect clarifies that claims that touch upon a natural law are 
not necessarily ineligible for patents, and that the judicial exceptions 
are limited to “claims that ‘amount to nothing more than observing or 
identifying the ineligible concept itself.’”174 For example, in Xlear, Inc. 
v. STS Health, L.L.C.,175 the U.S. District Court for the District of Utah 
found that a patent claiming a method of cleaning the nasopharynx of 
individuals by nasally administering a solution containing xylitol is 
patent-eligible subject matter.176 Though xylitol is a product of nature, 
 
 168. Id.  
 169. Id. at *6. Other post-Mayo/Myriad composition patents have been invalidated, including 
patents that cover single-stranded DNA primers, In re BRCA– & BRCA2–Based Hereditary 
Cancer Test Patent Litig., 774 F.3d 755, 761 (Fed. Cir. 2014), and cloned animals, In re Roslin 
Inst. (Edinburgh), 750 F.3d 1333, 1337 (Fed. Cir. 2014). 
 170. Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc., 827 F.3d 1042 (Fed. Cir. 2016). 
 171. Id. at 1046. 
 172. Id. at 1048. 
 173. Id. at 1051. 
 174. Bruce M. Wexler, Evan D. Diamond, Edwin Mok & Alexander Plushanski, Federal 
Circuit Upholds Patent Eligibility of a Method of Preserving Liver Cells, Giving Guidance on 
Applying Section 101’s Exclusion of Natural Laws, PAUL HASTINGS: INSIGHTS (July 7, 2016) 
(quoting CellzDirect, 827 F.3d at 1048), https://www.paulhastings.com/publications-
items/details/?id=b3eee969-2334-6428-811c-ff00004cbded [https://perma.cc/3QB9-JUA3].  
 175. Xlear, Inc. v. STS Health, LLC, No. 2:14-cv-00806-DN, 2015 U.S. Dist. LEXIS 167707 
(D. Utah Dec. 15, 2015). 
 176. Id. at *15. 
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the court held that a claim directed to “a new or novel application of 
xylitol” was patentable as an inventive process or method.177 
Another Federal Circuit case, Vanda Pharmaceuticals, Inc. v. 
West-Ward Pharmaceuticals International Ltd.,178 considered claims 
covering a method of treating schizophrenia with iloperidone by testing 
for whether a patient has a poor metabolizer genotype and then 
administering either a lower or higher dosage based on the results.179 
The court determined that the claims were not directed to the natural 
law governing the relationship between iloperidone, metabolism, and 
the specified health outcome, but to an application of that natural 
law.180 According to the court, “the claims here are directed to a 
specific method of treatment for specific patients using a specific 
compound at specific doses to achieve a specific outcome.”181 The 
patent was therefore found valid.182 A few other cases have upheld 
patents that are directed to natural laws or products under the second 
step of the Mayo/Alice test. One example is a patent that claims a 
method of approximating core body temperature based on readings 
from a lateral scan of the forehead and ambient temperature.183 
Another example is a claim that recites a method of monitoring drug 
metabolite levels that involves quantifying the levels in a urine sample 
in a way that accounts for the patient’s degree of hydration.184  
Those who find recent 35 U.S.C. § 101 jurisprudence murky and 
unclear with regards to the life sciences are in good company. Many 
critics argue that the Mayo/Alice test and its subsequent applications 
have “undermined certainty and protection for worthy inventions” in 
a number of ways.185 This uncertainty is exemplified by “conflicting 
Federal Circuit subject matter eligibility decisions regarding patents 
covering very similar technologies, and patents found to be ineligible 
in the US, but eligible in other countries.”186  
 
 177. Id. at *12–15. 
 178. Vanda Pharms., Inc. v. West-Ward Pharms. Int’l Ltd., 887 F.3d 1117 (Fed. Cir. 2018). 
 179. Id. at 1121. 
 180. Id. at 1136. 
 181. Id. 
 182. Id.  
 183. Exergen Corp. v. Kaz USA, Inc., 725 F. App’x 959, 961 (Fed. Cir. 2018). 
 184. Ameritox, Ltd. v. Millennium Health, LLC, 88 F. Supp. 3d 885, 890 (W.D. Wis. 2015).  
 185. Manny Schecter, Patent Subject Matter Eligibility 101, IPWATCHDOG (May 8, 2018), 
https://www.ipwatchdog.com/2018/05/08/patent-subject-matter-eligibility-101/id=96928/ [https:// 
perma.cc/YRJ5-BXMB]. 
 186. Id. 
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C. The Dubious Patentability of Phage Therapies Under the 
Mayo/Alice Test 
Although antibacterial resistance is becoming a more pressing 
concern and interest in phage-based therapeutics continues to grow, 
recent jurisprudence concerning patentable subject matter has cast a 
long shadow over the field. Phage-based therapeutic products would 
likely be patented under § 101 as a “composition of matter” or a “new 
and useful process” for treating an infection.187 Should the product be 
patented as a composition of matter, phages isolated from nature 
would undoubtedly be patent-ineligible under Myriad.188 Like the 
isolated DNA sequences in Myriad, naturally occurring phages would 
likely be considered a product of nature.189 One could argue that the 
isolation, purification, and sterilization of phages that is necessary to 
get the viruses into an administrable form would produce iterations of 
phages unlike any that exist naturally. However, a similar argument 
was rejected in Myriad; though the isolation of a sequence of DNA 
creates a nonnaturally occurring compound, the sequence itself was the 
subject matter of the claim.190 Should a phage therapy manufacturer 
attempt to patent its product by claiming a naturally occurring phage 
as a composition of matter, the manner in which the phage is claimed—
that is, as a purified therapeutic—would therefore likely be insufficient 
to save the patent under Myriad. 
Though naturally occurring phages are very unlikely to be 
patentable as compositions of matter, a stronger argument may be 
made for the patentability of modified phages.191 Current advances in 
synthetic biology have made it possible for researchers to alter the 
phenotypic expression of phages.192 Using CRISPR/Cas-9 or other 
methods, the viral DNA of a phage can be altered to achieve a number 
of ends, such as changing the range of hosts the phage can infect.193 
Phage display technology, which allows for the synthetic expression of 
different proteins on the surfaces of phages, is another technique of 
 
 187. 35 U.S.C. § 101 (2012). 
 188. Reardon, supra note 89. 
 189. Id.  
 190. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 580 (2013). 
 191. Reardon, supra note 89. 
 192. Antonia P. Sagona, Aurelija M. Grigonyte, Paul R. MacDonald & Alfonso Jaramillo, 
Genetically Modified Bacteriophages, 8 INTEGRATED BIOLOGY 465, 465 (2016).  
 193. Id. at 465–67. 
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synthetically modifying phages.194 Finally, phage genomes can be 
modified through directed evolution.195 Patents covering phage 
therapeutics that claim a modified phage as a composition of matter 
would more closely resemble the synthetic cDNA patents found valid 
in Myriad. Regardless, uncertainty in the validity of such patents 
remains. A January 2018 article authored by a life sciences patent 
expert argues that the wide availability and applicability of CRISPR to 
virtually all situations may threaten the patentability of CRISPR-
derived products in the future.196 Increasing reliance and knowledge 
that genetic engineering techniques can be used to achieve diverse 
results could cause the resulting patents to fail to be nonobvious as is 
required under other provisions of the patent statute.197 Phages 
developed through directed evolution may also be of dubious 
patentability as compositions of matter. Because directed evolution 
uses serial passaging—continuous culturing within a bioreactor—to 
guide or amplify a phage’s natural ability to evolve, the actual 
modification of the phage is due to naturally occurring evolutionary 
processes.198 Evolution is undoubtedly a natural law, and as one court 
explained, claims covering a product of nature whose only 
inventiveness come from an application of a law of nature are not 
sufficiently inventive under Mayo/Alice.199  
Method or process patents covering phage therapeutics—as 
opposed to composition of matter patents—may fare slightly better 
under Mayo/Alice. Even if phage products themselves are products of 
nature, methods of producing modified phages may be patent eligible 
if they claim more than an application of a law or product of nature 
using “well-understood, routine, conventional activit[ies] already 
 
 194. Id. at 468.  
 195. Id. at 467–68. 
 196. See Jacob S. Sherkow, The CRISPR Patent Landscape: Past, Present, and Future, 1 
CRISPR J. 5, 7–8 (2018) (noting that the “reasonable expectation of success in using CRISPR as 
a genome-editing tool for any system or cell type” and the obviousness of “using CRISPR to 
accomplish these goals” discourage “the patenting of follow-on inventions”).  
 197. 35 U.S.C. § 103 (2012); see Sherkow, supra note 196, at 7 (“Now that the power of 
CRISPR as a genome-editing technology has been elucidated, is any future application of it 
nonobvious?”).  
 198. See Sagona et al., supra note 192, at 467–68 (explaining the process by which phages can 
be directed to evolve through “serial passaging” in a bioreactor). 
 199. See Nat. Alternatives Int’l, Inc. v. Creative Compounds, LLC, No. 16-cv-02343-H-AGS, 
2017 WL 3877808, at *6 (S.D. Cal. Sept. 5, 2017) (“[E]mploying a dietary supplement to 
administer beta-alanine—a natural phenomenon—to achieve a high level of carnosine synthesis 
in a human—applying a natural law—is insufficient to render the claims at issue patent 
eligible . . . .”). 
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engaged in by the scientific community.”200 However, the use of genetic 
engineering, phage display, and directed evolution methodologies are 
already common practices for modifying phages, making such method 
claims dubious under both § 101 and § 103.201 
Arguably the best option for procuring valid phage therapy 
patents would be to mimic the construction of patents seen in Xlear as 
a novel method of treatment. Like phages, xylitol is a natural 
product.202 However, the Xlear patents were valid only insofar as they 
claimed the process by which that natural product would be used in the 
treatment of a condition for which it had never been used.203 Though 
general knowledge of the ability to treat bacterial infections with 
phages has existed for decades, an argument could be made that 
developing a treatment method that uses a new strain or combination 
of phages that has never been used to treat a certain bacterial infection 
is an inventive application of a natural product. However, the authority 
and persuasive power of Xlear and its reasoning will remain limited 
unless affirmed by higher courts. 
D. Current Patenting Efforts and Litigation in the Phage Therapy 
Field 
While the patentability of phage therapeutics remains uncertain, 
phage therapy developers continue to apply for patents in the hopes of 
acquiring enforceable protection. Intralytix reports protecting its 
investment through the use of “a multi-prong [patenting] approach, 
which provides broad and strong protection ranging from protecting 
specific bacteriophages . . . to [protecting] methods and applications of 
those bacteriophages in various settings.”204 Intralytix’s “throw 
everything at the wall to see what sticks” patenting strategy sheds light 
on the inner workings of the industry as a whole. Many of the patents 
relating to phage therapeutics that have been filed, of which there are 
relatively few, employ vastly different strategies for protection. These 
strategies include claiming methods of treatment in which phages are 
 
 200. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 79–80 (2012). 
 201. See Sagona et al., supra note 192, at 466–68 (discussing the use of genetic engineering, 
phage display, and directed evolution methodologies on phages). 
 202. Xlear, Inc. v. STS Health, L.L.C., No. 2:14-cv-00806-DN, 2015 U.S. Dist. LEXIS 167707, 
at *12 (D. Utah Dec. 15, 2015). 
 203. Id. at *12–15. 
 204. Patents, INTRALYTIX, http://www.intralytix.com/index.php?page=patents [https://
perma.cc/6NK2-9L8Q]. 
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administered,205 patenting phage enzymes as opposed to full phages,206 
claiming the use of phages in animals,207 and patenting strains of phages 
directly.208 While the diversity of these strategies may be a product of 
necessity, it is likely that such wide variety, at least to some degree, 
reflects an uncertainty among those invested in phage product R&D as 
to how best to achieve strong patent protection. Alternatively, these 
diverse strategies may reflect that phage patents still hold some value 
as signaling mechanisms for investors, regardless of the actual 
enforceability of the patents. This shotgun approach to patent claims 
may also reflect expectations in the field that the law under Mayo, 
Myriad, and Alice will soon be changed, albeit in an unknown 
direction. 
Very few suits regarding the validity of patents pertaining to 
phages have been brought in recent years. Furthermore, most of these 
suits involve patents that only tangentially touch on phages,209 and they 
analyze validity based on challenges outside of § 101.210 Because no 
case has been brought yet that directly addresses the validity of phage 
therapy as patentable subject matter, the uncertainty surrounding 
phage therapeutics remains. As more players enter the field, the 
likelihood of an impending clash between competitors’ patents is ever 
increasing. 
IV.  INCENTIVIZING INVESTMENT IN PHAGE THERAPIES THROUGH 
NONPATENT MEANS 
Patent protection has generally been “considered the gold 
standard for invention protection,” due in large part to the strength, 
 
 205. See U.S. Patent No. 9,850,467 (claiming “[a] method for improving the state of health of 
patients infected with adenovirus HadV-5, comprising providing [and administering to the 
patient] a T4 phage preparation comprising an effective amounts of T4 phage to inhibit the 
proliferation of adenovirus HadV-5 by 50%”). 
 206. See U.S. Patent No. 9,034,322 (claiming compositions “comprising an effective amount 
of [certain] isolated lysin polypeptide[s]”). 
 207. See U.S. Patent No. 9,433,653 (claiming “[a] method of treating or reducing mortality 
due to E. coli diarrhoea in a non-human animal subject” that involves the use of “a composition 
comprising as the active ingredient an effective concentration of the isolated bacteriophage 
EK88P-1”). 
 208. See U.S. Patent No. 8,440,446 (claiming “[a]n isolated bacteriophage strain specific 
against bacteria belonging to the genus Enterococcus”). 
 209. See, e.g., Regeneron Pharms., Inc. v. Merus B.V., 144 F. Supp. 3d 530, 574–75 (S.D.N.Y. 
2015) (considering a phage-derived recombination system). 
 210. See, e.g., In re Droge, 695 F.3d 1334, 1335–36 (Fed. Cir. 2012) (determining whether a 
claim tangentially related to phages was invalid under 35 U.S.C. § 103). 
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ease, and breadth with which patents can be enforced.211 A therapeutic 
with limited patent protection is thus unlikely to be a financially 
attractive investment for manufacturers under normal market 
conditions.212 However, phage therapy is not the first important field to 
suffer from being underincentivized or underprotected by the existing 
patent framework.213 Finding workable alternatives or supplements to 
patent protection has proven successful in other fields and has strong 
potential in the field of phage therapeutics. 
Trade secrecy—one of the most common nonpatent protections 
used in the biopharmaceutical industry—is already being employed by 
phage therapy developers. While trade secrecy is an easy way to 
achieve some protection for phage therapies, this protection is limited. 
A strong case can be made for establishing a period of regulatory 
exclusivity for phage therapies to supplement trade secrecy, though 
such periods are generally granted only for a short time. Although they 
do not address the threats posed by competitors, government-
sponsored research funding and collaborations, as well as alternative 
payment models for phage therapies could provide additional 
incentives in the field by addressing cash flow issues at different points 
in the product’s life cycle.  
A. Trade Secrecy 
Chief among nonpatent protections in the pharmaceutical field is 
trade secrecy. A trade secret is confidential information that gives a 
business a competitive edge.214 These rights are judicially enforceable 
when the secret is not generally known to the public, and derives some 
economic benefit from being unknown, and is kept secret through 
 
 211. John Artz, Brandon Debus & Franklin Smith, To Disclose or Not to Disclose: Trade 
Secrets vs. Patents, LAW360 (Sept. 25, 2017), https://www.law360.com/articles/964200/to-disclose-
or-not-to-disclose-trade-secrets-vs-patents [https://perma.cc/37GW-BSXH]. 
 212. Alexandra Henein, What Are the Limitations on the Wider Therapeutic Use of Phage?, 3 
BACTERIOPHAGE, Apr.–June 2013, 4–5 (2013).  
 213. For example, discoveries in the field of basic research are generally patent ineligible as 
laws or products of nature; these discoveries are nevertheless highly important building blocks 
for future innovation. Instead of relying on private patent rights, basic research is incentivized by 
an alternative model, whereby public funding is awarded to universities that conduct such 
research. See Désirée Schauz, What is Basic Research? Insights from Historical Semantics, 52 
MINERVA 273, 318–19 (2014) (detailing the development of “basic research” as a concept so 
federal funding could be secured for research that does not produce immediate commercial 
benefit). 
 214. Tara Nealey, Ronald M. Daignault & Yu Cai, Trade Secrets in Life Science and 
Pharmaceutical Companies, COLD SPRING HARBOR PERSP. MED., Nov. 2014, 3. 
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reasonable efforts.215 Trade secrecy offers protection for information 
that may not be eligible for patent protection.216 It also has additional 
competitive benefits; unlike patents, trade secrets do not require 
disclosure to competitors, and they can be held indefinitely.217 As such, 
using trade secrecy to protect investments has become the norm in a 
number of life sciences fields where patent protection is insufficient.218 
Two fields in which trade secrecy has played an important role in 
incentivizing competition and innovation are biologics and genetic 
testing. In the biologics space, the complexity and sensitivity of the 
product requires the development of highly sophisticated 
manufacturing processes.219 However, it can be difficult to protect that 
investment through manufacturing process patents, as they can be 
difficult to enforce and offer only temporary protection.220 Trade 
secrecy has therefore been adopted by many biologics producers to 
protect intellectual property relating to manufacturing processes.221 
Because trade secrecy extends indefinitely and the details of those 
processes are not forced into the public domain, fewer biosimilar 
competitors find it financially viable to reverse engineer the complex 
processes with enough precision to produce acceptable biosimilars.222 
This indefinite pseudomonopoly makes trade secrecy extremely 
valuable to biologics manufacturers.223 
Trade secrecy could have a number of applications for phage 
therapy manufacturers. As is the case with biologics, keeping 
production processes as trade secrets could provide a competitive edge 
by making it harder for others to reverse engineer similar phage 
products.224 Innovative methods of purifying, preparing, amplifying, or 
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storing phages would be protectable as trade secrets. AmpliPhi 
Biosciences has already incorporated trade secrecy into its business 
model, reporting in its 2018 SEC Annual Report that to “protect [its] 
proprietary know-how, which is not patentable, and for inventions for 
which patents may be difficult to enforce, [it] currently and will in the 
future rely on trade secret protection . . . to protect [its] interests.”225 
The significant genetic variability of phages may also lead to the 
building of large phage libraries that can be used to create personalized 
treatments. Such libraries could possibly be maintained as trade 
secrets. However, this trade secrecy would not be boundless. 
Knowledge of the strains of phages themselves, of the composition of 
a cocktail of phages, and of their efficacy against a certain bacterium 
would likely no longer be considered a trade secret once the product is 
administered to members of the public. Therefore, while trade secrecy 
does provide some value for phage therapy manufacturers, its 
protection is likely limited to certain internal processes that would be 
difficult to replicate.226 
Overreliance on trade secrecy may also have its drawbacks. As 
with biologics and biosimilars, maintaining extensive trade secrecy 
over phage product manufacturing processes may ratchet up the costs 
of follow-on innovation.227 Hiding the discovery of new strains of 
phages in private silos may also inhibit the efficiency of basic and 
applied research228 by shielding the “building blocks of human 
ingenuity” from potential future phage researchers and inventors.229 
Furthermore, phages have possible applications outside of human 
health in industries ranging from food safety to environmental 
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sanitation to animal health.230 Keeping new strains or related 
information secret could have the unfortunate off-target effect of 
creating deadweight loss in non-health industries by hiding from 
potential noncompetitor inventors the key building blocks for 
innovation in their fields.  
At bottom, while trade secrecy holds some value for phage 
therapy developers, it is lacking in a number of ways. In the absence of 
patent protection, additional solutions are likely needed to supplement 
trade secrecy in the phage therapeutic field. 
B. Regulatory Exclusivities 
Another alternative for incentivizing innovation in phage 
therapeutics is regulatory exclusivity. A number of different regulatory 
exclusivities are currently awarded by the FDA to incentivize 
investment by pharmaceutical companies.231 One of the broadest 
categories of exclusivity offered by the FDA is for new chemical 
entities, which are drugs that contain no active moiety—a molecule or 
ion that is responsible for the pharmacological effect of the drug—that 
has previously been approved by the FDA.232 Exclusivity granted for a 
new chemical entity rewards manufacturers with a five-year period of 
data exclusivity, during which time no competitor can be approved to 
market a product that relies on the originator’s safety and efficacy 
data.233 Relying on an innovator drug’s safety and efficacy data allows 
follow-on manufacturers to avoid the significant expenses associated 
with full clinical trials so they can bring a cheaper version of the drug 
to market through a generic approval pathway established by 
Congress.234 When this cheaper route to regulatory approval is not 
available, generic manufacturers are unlikely to enter the market and 
innovator drugs can maintain their market share. This kind of data 
exclusivity, however, may provide little incentive for investing in phage 
therapeutics, as no similar generic approval pathway currently exists 
for phage products.  
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A more sweeping type of exclusivity is granted by the FDA for 
orphan drugs, which treat diseases affecting less than 200,000 people in 
the United States or which have no hope of recovering R&D costs.235 
Orphan drug exclusivity provides seven years of market exclusivity, 
during which time no other application for the same drug for the same 
disease can be approved.236 Market exclusivity is therefore broader 
than data exclusivity in that it prevents a product from reaching the 
market even if it is fully supported by original data.237 This has led some 
to describe the market exclusivity granted by the Orphan Drug Act238 
as “similar to a patent on a particular use of a drug, [that is] enforced 
by FDA.”239 Since orphan drug exclusivity was established, there has 
been a marked increase in drug approvals for orphan diseases, and 
there has been more interest by manufacturers in the development of 
orphan drugs.240  
Scholars have suggested that adopting a reward similar to orphan 
drug exclusivity would be an appropriate incentive for phage therapy 
innovation.241 Similar to orphan drugs, phage therapy products would 
be unlikely to recoup their costs due to low sales volume. Phage 
therapies are only taken for a short time period, and they are highly 
targeted; this means that phage therapies have a small customer base 
that would only purchase the drugs in small quantities.242 The principle 
of effective antibiotic stewardship, whereby newer and stronger drugs 
are prescribed less to fend off antibiotic resistance, would also impair 
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phage therapy sales.243 Market exclusivity would help phage therapy 
manufacturers recoup their costs by allowing them to extract value 
from their products over a nonpatent monopoly period. Because of the 
dubious patentability of phage therapeutics, appropriately tailored 
market exclusivity could serve well as a stand in for patents for 
protecting phage therapy investment.  
Congress recognized the value of regulatory exclusivities for 
antibacterial innovation in the 2012 Generating Antibiotic Incentives 
Now (“GAIN”) Act.244 The GAIN Act makes certain qualified 
infectious disease products (“QIDPs”) eligible for fast track and 
priority review by the FDA.245 It also extends previously established 
exclusivities, including new chemical entity exclusivity and orphan 
drug exclusivity, by five years for QIDPs.246 While the GAIN Act is 
encouraging, it is still a flawed fit for phage therapies since the 
exclusivities extended by the Act are not well tailored to the needs of 
the industry. Establishing a unique QIDP market exclusivity period 
would more clearly and comprehensively protect phage therapy 
investments and serve as a strong complement to trade secrecy. 
However, because market exclusivities generally protect products for 
a shorter period than patent protection,247 additional incentives may 
still be necessary. 
C. Governmental Incentives 
As the GAIN Act demonstrates, governmental efforts have the 
potential to play a pivotal role in incentivizing the development of 
phage therapeutics. Indeed, increasing awareness of the promise of 
phage therapies within the government and nonprofit sectors has 
already prompted a number of such efforts.248  
Outside of the FDA, two main players in the field are NIAID and 
the Biomedical Advanced Research and Development Authority 
(“BARDA”). NIAID’s efforts were initiated by President Obama’s 
National Action Plan for Combating Antibiotic-Resistant Bacteria, 
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which directed governmental agencies to support research into the use 
of “phage and phage-derived lysins to kill specific bacteria,” as well as 
other nontraditional antibiotics.249 As part of this initiative, NIAID 
awarded over $5 million in funding for 24 research projects, seven of 
which involved phages.250 This funding has already proved fruitful; for 
example, one NIAID-funded study used phage lysins to develop a 
small molecule capable of inhibiting the growth and lethality of 
Staphylococcus aureus and Bacillus anthracis.251 While NIAID’s efforts 
are mostly focused in the field of basic research, BARDA supports the 
advanced development of medical products aimed at addressing public 
health threats, including “pandemic influenza, and emerging infectious 
diseases.”252 As part of this mission, BARDA helped launch and fund 
the Combating Antibiotic Resistant Bacteria Biopharmaceutical 
Accelerator, a public-private partnership that provides funding and 
support for private biotechnology companies engaged in developing 
products that treat antibiotic-resistant bacteria.253 
Grant funding is not the only relevant incentive being considered 
by the government. In March 2017, the Reinvigorating Antibiotic and 
Diagnostic Innovation Act was introduced into Congress.254 Similar to 
the Orphan Drug Act, this legislation, which appears to have since died 
in committee, would have provided manufacturers up to a 50 percent 
tax credit for the expenses associated with clinical testing for a QIDP.255 
Another bill, the Promise for Antibiotics and Therapeutics for Health 
Act, sought to establish a new approval pathway for antibacterial drugs 
aimed at treating serious infections or diseases in limited 
populations.256 However, that bill died in Congress.257 Another piece of 
legislation, which met a similar fate, attempted to extend Medicare 
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coverage for new antibiotic therapies to insulate prescribing decisions 
from cost concerns.258  
D. Alternative Payment Models 
Finally, alternative payment models have recently been theorized 
as a novel answer to the issue of underincentivized, low-sales-volume 
drugs. Delinkage models suggest establishing a predetermined 
financial reward for any developer who brings a new product to 
market, thus “delinking” the connection between usage and revenue. 
One such model would be to reward developers with tradable vouchers 
that extend patent or regulatory exclusivity, which are highly valuable 
and can be sold to blockbuster drug manufacturers for hundreds of 
millions of dollars. Delinkage was incorporated into the Improving 
Access to Affordable Prescription Drugs Act, which was introduced in 
Congress in March 2017, although it appears to have since been 
unfortunately abandoned.259 This legislation would have offered 
monetary prizes from a $2 billion fund for antimicrobial developers 
who developed a high-priority drug.260 
Other alternative payment models could have the dual benefits in 
the field of antimicrobials of encouraging appropriate antibiotic use 
and appropriately compensating manufacturers.261 Population-based 
payment models compensate developers based on the value of the drug 
to society, linking revenue not to sales volume, but to indicators of 
value such as the availability of the drug when needed, appropriate use 
of the drug by physicians, and the continued effectiveness of the 
drug.262 Because population-based payment theories are rooted in the 
principle of effective stewardship, under such a model “having a drug 
for a low prevalence infection would be highly valuable.”263 The 
applicability of such payment models to phage therapeutics is quite 
clear. Because of the narrow host range of any one phage-based 
product, they will likely never replace traditional, widely used, broad-
 
 258. H.R. 512 - DISARM Act of 2015, CONGRESS.GOV, https://www.congress.gov/bill/114th-
congress/house-bill/512 [https://perma.cc/FY2B-9R2C]. 
 259. S. 771, 115th Cong. (2017). 
 260. Id. § 301. 
 261. See GREGORY W. DANIEL ET AL., DUKE-MARGOLIS CTR. FOR HEALTH POL’Y, VALUE-
BASED STRATEGIES FOR ENCOURAGING NEW DEVELOPMENT OF ANTIMICROBIAL DRUGS 12–
13 (2017) (describing several potential models for encouraging antimicrobial development).  
 262. Id. at 13. 
 263. Id. 
TODD IN PRINTER FINAL (DO NOT DELETE) 12/13/2018  11:07 AM 
2019] PATENTABILITY OF PHAGE THERAPEUTICS 805 
spectrum antibiotics.264 However, their targeted nature and 
adaptability make them an extremely powerful last line of defense 
against particularly aggressive pathogens.265 As such, phage therapies 
are a prime example of a drug that provides very high value to a small 
population. 
CONCLUSION 
Innovation in the pharmaceutical industry currently relies heavily 
on patent protection to incentivize investment by providing strong 
monopoly pricing power for new drugs. However, recent § 101 
jurisprudence will likely make patenting phage products difficult, if not 
entirely impossible. Without strong patent protection, alternative 
incentives are likely needed to encourage the level of innovation that 
is necessary to address the antibiotic resistance crisis. Trade secrecy 
and process patents will likely remain somewhat valuable for 
protecting phage product manufacturing processes. However, 
establishing an FDA-mandated market exclusivity for phage therapies, 
similar to orphan drug exclusivity, would likely be more effective in 
creating patent-like monopoly power. Because regulatory exclusivities 
generally last for a shorter time than the effective life of a patent, 
additional incentives—such as financial subsidies for R&D through the 
government or nonprofits, or the decoupling of revenue from sales 
volume—will likely be needed for robust innovation in the phage 
therapeutics market. With the specter of a catastrophic antibiotic-
resistant bacterial epidemic likely looming in the near future,266 it is 
imperative that innovative phage therapies and other nontraditional 
antimicrobials are properly incentivized before it is too late. 
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